In the post-genomic era, cytokine or antibody therapy has received attention for advanced drug therapies. Indeed, attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancer, hepatitis and autoimmune conditions. Unfortunately, however, the utilization of bioactive proteins in clinical practice is often limited because of their inherent instability and pleiotropic actions in vivo. Our laboratory aims to overcome two major problems, details of which will be addressed in separate sections to follow. (i) Development of a powerful system to rapidly create functional mutant proteins (muteins) with enhanced receptor a‹nity and receptor speciˆcity using a phage display technique (biological DDS). (ii) Establishment of a novel polymer-conjugation system to dramatically improve in vivo stability and selectively of bioactive proteins (polymeric DDS). We are currently attempting to combine both approaches to create a protein-drug innovation system to further promote pharmaco-proteomic-based drug development. In this review, we will describe DDS-based technology for creating functional mutants for advanced medical applications, using tumor necrosis factor-alpha (TNF) as an example.
. Creation of Functional Mutant Proteins Using Phage Display
Phage display system has the following main characteristics: 1) proteins can be displayed on the outer shell of the phage where they can interact with their target molecules, such as a receptor or antigen. These protein-displaying phage particles are produced by the integration of a foreign gene into the 5'-terminus of the gene that encodes the outer shell of the phage (i.e., g3p) in phagemid vector or phage genome; 2) the genotype of this phage (the foreign gene inside the phage clone), corresponds with the phenotype (the protein displayed on the phage's surface); 3) phage particles or``libraries'', can readily be made, which consist of billions of varieties of protein; 4) a selected phage from the library can be readily ampliˆed by infection of a host bacterial cell. It is therefore possible to screen for, and then isolate, high-a‹nity binders to target molecules from the phage library. 
1) The bioactivities of wild-type TNF (wtTNF) and K90R were measured by cytotoxic assay using HEp-2 cells in the presence of cycloheximide (50 mg/ml). Experimental data were analyzed by a logistic regression model to calculate the mean eŠective concentration (EC50). 
. Antagonistic Activities of the R1antTNF
Serial dilutions of TNF-T2 were mixed with human wtTNF (20 ng/ml) and then applied to HEp-2 cells. After 18 h, the inhibitory eŠects of TNF-T2 on the cytotoxicity of wtTNF were assessed by using the methylene blue assay. The absorbance of cells without wtTNF was plotted as 100 percent viability. The data represent the mean±SD (n＝3). The severity of arthritis in CIA mice (n＝10) treated with PBS, PEG-T2 (1 mg twice a day) for three weeks from 23 day was assessed every day using an established macroscopic scoring system. Data of severity represent the mean±SEM. 
